Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations

Q: What type of study is this?

This is a Experimental Study study.

Jennifer A. Simonovich; Arun Wanchoo; Ryan Clark; Junha Park; Ayumi Shigemoto; Benjamin G. Keselowsky; Gregory A. Hudalla

doi:10.1039/d5me00106d

January 1, 2025Molecular Systems Design & EngineeringOpen Access

Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations

View Full Paper

Ask AI

Bookmark

Share

Key Points

Selective mutations of cysteine to serine enhance the activity of indoleamine 2,3-dioxygenase, leading to better therapeutic outcomes.
The engineered enzyme offers insights into how redox control affects immunomodulatory functions, opening new avenues for therapy.
These mutations could stabilize the enzyme's function in hostile environments, increasing the efficacy of immunotherapy approaches.
Results suggest that understanding enzyme activity regulation through redox mechanisms is vital for advancing protein therapeutics.

Implication

Engineering modifications improve indoleamine 2,3-dioxygenase activity, highlighting potential in immunotherapy.

Abstract

Indoleamine 2,3-dioxygenase is an immunomodulatory enzyme that shows great promise when delivered exogenously as a protein therapeutic. However, IDO activity is under complex redox control, mediated in part by multiple...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Simonovich et al. (2025) studied this question.

synapsesocial.com/papers/68d464f131b076d99fa64259 https://doi.org/10.1039/d5me00106d

View Full Paper

Ask AI

Bookmark

Share

Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations

Key Points

Implication

Abstract

Discussion

Cite This Study

Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading